Melatonin attenuates acute kidney injury in rats: modulation of the p53–PUMA/Bcl-2–Bax apoptotic signaling axis
Naunyn-Schmiedeberg's Archives of Pharmacology, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s00210-026-06026-w
- Dergi Adı: Naunyn-Schmiedeberg's Archives of Pharmacology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, Chimica, EMBASE, MEDLINE, Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: Acute kidney injury, Melatonin, P53, PUMA, NOXA, Bax, Bcl-2
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Acute kidney injury (AKI) is characterized by oxidative stress–mediated tubular damage and activation of apoptosis-related signaling pathways. This study aimed to investigate the potential protective effect of melatonin on renal injury, focusing on histopathological alterations, apoptosis-related gene expression, and renal function parameters in an experimental AKI model. Twenty-eight rats were randomly assigned to four groups: Control, AKI, AKI + Solvent (1% ethanol), and AKI + Melatonin (20 mg/kg, intraperitoneal). AKI was induced by 45 min of renal ischemia followed by 24 h of reperfusion. At the end of the experimental period, kidney tissues were collected for histopathological evaluation using hematoxylin–eosin (H&E) and periodic acid–Schiff (PAS) staining. Apoptosis-related proteins (p53, PUMA, NOXA, Bax, and Bcl-2) were analyzed by immunofluorescence, and the expression levels of the corresponding genes were quantified using real-time polymerase chain reaction (qRT-PCR). Renal function was assessed by measuring serum creatinine and blood urea nitrogen (BUN) levels. AKI induced marked histopathological damage compared with the Control group (p < 0.001), whereas melatonin treatment significantly attenuated tissue injury. Immunofluorescence analysis demonstrated increased positive cell index (PCI) values for p53, PUMA, and Bax alongside decreased Bcl-2 PCI in the AKI group (p < 0.05), while NOXA PCI remained unchanged (p > 0.05). Notably, melatonin administration resulted in a statistically significant reduction in the Bax/Bcl-2 ratio compared to the untreated AKI group (p < 0.05), indicating a shift toward cellular survival at the protein level. No statistically significant differences were detected in apoptotic gene expression at the mRNA level. Serum creatinine levels increased significantly in the AKI group (p < 0.001). Melatonin treatment is associated with a modulation of key components within the p53–PUMA/Bcl-2–Bax apoptotic signaling axis in renal tissue following ischemia–reperfusion injury.